Jiangsu Zhenjiang Newenergy Equipment Co.Ltd(603507) shareholders plan to reduce their holdings of no more than 1% of the company’s shares
According to the announcement of Jiangsu Zhenjiang Newenergy Equipment Co.Ltd(603507) , Jiahong Xingxing, a shareholder with a shareholding of 5.17%, plans to reduce the company’s shares by means of centralized bidding within 3 months after 15 trading days from the date of the announcement of the reduction plan, i.e. no more than 1256314 shares, i.e. no more than 1% of the company’s total share capital.
Beijing Succeeder Technology Inc(688338) performance express: net profit in 2021 increased by 40% year-on-year
Beijing Succeeder Technology Inc(688338) release performance express. In 2021, the company realized an operating revenue of 239915362.66 yuan, a year-on-year increase of 7.88%; The net profit attributable to the owners of the parent company was 97368830.48 yuan, a year-on-year increase of 40.73%. The basic earnings per share is 1.19 yuan.
dzd4205, a product under development by Dizhe pharmaceutical, was recognized by FDA fast track
Dizhe pharmaceutical announced that the company’s product dzd4205 under research has been awarded the “fast track design” (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent refractory peripheral T-cell lymphoma (PTCL). Dzd4205 is the world’s first Jak1 highly selective inhibitor for PTCL. According to the regulations, once the new drug under research and development obtains the FTD qualification, it will have the opportunity to enjoy a series of policies to accelerate drug development. Dzd4205 won FTD this time, which is helpful for the company to improve the communication efficiency with FDA and obtain the guidance of FDA in the process of drug development. It is also expected to shorten the time of product listing review through priority review and promote the commercialization of products as soon as possible.
Changchun Bcht Biotechnology Co(688276) performance express: the net profit in 2021 decreased by more than 40% year-on-year
Changchun Bcht Biotechnology Co(688276) release performance express. In 2021, the company’s total operating revenue was 1202026600 yuan, a year-on-year decrease of 16.60%; The net profit attributable to the owners of the parent company was 243553400 yuan, a year-on-year decrease of 41.77%. The basic earnings per share is 0.62 yuan.
Hengdian Entertainment Co.Ltd(603103) performance express: net profit in 2021 turned from loss to profit
Hengdian Entertainment Co.Ltd(603103) release performance express. In 2021, the company’s operating revenue was 2365695900 yuan, a year-on-year increase of 139.02%; The net profit attributable to the shareholders of the listed company was 13.6397 million yuan, turning losses into profits year-on-year. The basic earnings per share is 0.02 yuan. A loss of 480 million yuan in the same period last year. The turnaround of performance in this period is mainly due to the effective control of the epidemic and the substantial increase of the company’s operating income.
The holding subsidiary of Shanghai Shyndec Pharmaceutical Co.Ltd(600420) signed the drug marketing license transfer contract
Shanghai Shyndec Pharmaceutical Co.Ltd(600420) announced that in order to enrich the company’s product line in the cardiovascular field, zhijunpingshan, a holding subsidiary, signed the drug listing license transfer contract with Jilin Deshang, and Jilin Deshang transferred the drug listing license of olmesartan axetil amlodipine tablets (20mg / 5mg) it was applying for registration to zhijunpingshan, with a total transfer fee of 33.8 million yuan. Olmesartan axetil amlodipine tablet is a new generation of single compound antihypertensive drug. It has clear antihypertensive effect, small adverse effect and is not affected by food. It is clinically suitable for the treatment of essential hypertension.
Guizhou Zhenhua E-Chem Inc(688707) performance express: the net profit in 2021 turned from loss to profit
Guizhou Zhenhua E-Chem Inc(688707) release performance express. In 2021, the company realized an operating revenue of 5514.9004 million yuan, a year-on-year increase of 432.07%; The net profit attributable to the owner of the parent company was 412592800 yuan and turned losses into profits. A loss of 170 million yuan in the same period last year. In 2021, the power battery market of new energy vehicles grew rapidly, and the sales volume and revenue of the company’s cathode materials increased significantly year-on-year. Among them, the proportion of sales volume and revenue of high nickel ternary materials increased significantly due to matching the needs of downstream customers.
Kaile Science And Technology Co.Ltd.Hubei(600260) applied for bankruptcy reorganization by creditors
St Keller announced that on February 17, 2022, the company received a notice from Jingzhou intermediate people’s court that the creditor Shashi branch of Hubei Xinqing plasticization Co., Ltd. proposed bankruptcy reorganization of the company to Jingzhou intermediate people’s court because the company could not pay off its due debts and obviously lacked solvency.
Lanzhou Lishang Guochao Industrial Group Co.Ltd(600738) performance express: net profit in 2021 increased by 66% year-on-year
Lanzhou Lishang Guochao Industrial Group Co.Ltd(600738) release performance express. In 2021, the company realized an operating revenue of 646955200 yuan, a year-on-year increase of 7.95%; The net profit attributable to the shareholders of the listed company was 143.738 million yuan, a year-on-year increase of 65.86%. The basic earnings per share is 0.186 yuan. In 2021, the national epidemic was gradually and effectively controlled. Under the condition of continuously improving the renewal rate and rental rate of the company’s professional market leasing business, the operating revenue increased significantly, resulting in an increase in profits. The income from surveying and mapping settlement of sold properties increased, resulting in an increase in profits.
